SynthesisOncotarget2016

Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials.

Claudia Marchetti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.